The biotech company released news that they are working a drug to deal with prostate cancer. Apparently investors appetite is strong for prostate cancer drugs. Shares of GVBP were up .024 cents or %20 in early OTCBB trading. Other favorites were down in early trading WGAT and SPNG were each down %20 in early trading.
Genova Biotherapeutics Inc. News
The peptide, called Prostaganin, is a 21-amino compound which is highly reactive to prostate cancer cells, and has the ability to specifically target them. In laboratory experiments, Prostaganin has demonstrated an ability to preferentially bind to and disrupt certain negatively charged components of the membranes of prostate cancer cells.